Found 162 results for Cardiology

Webinars

button
button
button
button

Videos

11 Mar

Heart Failure Peer Exchange Forum- Mumbai

Eminent Cardiologists from Mumbai share their practical experiences and insights on managing Heart Failure cases

button
15 Feb

Heart Failure Peer Exchange Forum- Kolhapur

Eminent Cardiologists from Kolhapur share their practical experiences and insights on managing Heart Failure cases

button
13 Feb

Heart Failure Peer Exchange Forum-Bangalore

Eminent Cardiologists from Bangalore share their practical experiences and insights on managing Heart Failure cases

button

Courses

button
button
button

Medshorts

1Min Read
23 Jul

Higher Treatment Satisfaction and Convenience scores in patients treated with edoxaban

A recent study suggests that patients with atrial fibrillation after successful transcatheter aortic valve replacement (TAVR) showed significantly more satisfied Treatment Satisfaction and Convenience scores with edoxaban. The results of this study were published in The American Journal of Cardiology.

The ENVISAGE-TAVI AF trial was a prospective, randomized, open-label study that included patients who were randomized to receive either edoxaban (n=585) or VKA-treated (n=522). Pre and post-TAVR Treatment Satisfaction and Convenience were analyzed using the Perception of Anticoagulation Treatment Questionnaire (PACT-Q), that included assessment at baseline (PACT-Q1) and ≥1 post baseline assessment (PACT-Q2). Patients stratified by pre-TAVR anticoagulant (NOAC, VKA, or no NOAC/VKA) were included in subanalyses.

After TAVR (Transcatheter Aortic Valve Replacement), edoxaban-treated patients showed significantly higher Treatment Satisfaction and Convenience scores compared with VKA-treated patients across all time points. Among edoxaban-treated patients, those who received VKAs pre-TAVR were reportedly more satisfied with treatment than those who received non-vitamin K oral anticoagulants (NOACs) or NOACs/VKAs.

Based on the above results, it can be concluded that patients with atrial fibrillation who were administered edoxaban post-TAVR may show significantly higher Treatment Satisfaction and Convenience scores compared with those who received VKAs.

Higher Treatment Satisfaction and Convenience scores in patients treated with edoxaban

A recent study suggests that patients with atrial fibrillation after successful transcatheter aortic valve replacement (TAVR) showed significantly more satisfied Treatment Satisfaction and Convenience scores with edoxaban. The results of this study were published in The American Journal of Cardiology.

The ENVISAGE-TAVI AF trial was a prospective, randomized, open-label study that included patients who were randomized to receive either edoxaban (n=585) or VKA-treated (n=522). Pre and post-TAVR Treatment Satisfaction and Convenience were analyzed using the Perception of Anticoagulation Treatment Questionnaire (PACT-Q), that included assessment at baseline (PACT-Q1) and ≥1 post baseline assessment (PACT-Q2). Patients stratified by pre-TAVR anticoagulant (NOAC, VKA, or no NOAC/VKA) were included in subanalyses.

After TAVR (Transcatheter Aortic Valve Replacement), edoxaban-treated patients showed significantly higher Treatment Satisfaction and Convenience scores compared with VKA-treated patients across all time points. Among edoxaban-treated patients, those who received VKAs pre-TAVR were reportedly more satisfied with treatment than those who received non-vitamin K oral anticoagulants (NOACs) or NOACs/VKAs.

Based on the above results, it can be concluded that patients with atrial fibrillation who were administered edoxaban post-TAVR may show significantly higher Treatment Satisfaction and Convenience scores compared with those who received VKAs.

button
1Min Read
23 Jul

Higher Treatment Satisfaction and Convenience scores in patients treated with edoxaban

A recent study suggests that patients with atrial fibrillation after successful transcatheter aortic valve replacement (TAVR) showed significantly more satisfied Treatment Satisfaction and Convenience scores with edoxaban. The results of this study were published in The American Journal of Cardiology.

The ENVISAGE-TAVI AF trial was a prospective, randomized, open-label study that included patients who were randomized to receive either edoxaban (n=585) or VKA-treated (n=522). Pre and post-TAVR Treatment Satisfaction and Convenience were analyzed using the Perception of Anticoagulation Treatment Questionnaire (PACT-Q), that included assessment at baseline (PACT-Q1) and ≥1 post baseline assessment (PACT-Q2). Patients stratified by pre-TAVR anticoagulant (NOAC, VKA, or no NOAC/VKA) were included in subanalyses.

After TAVR (Transcatheter Aortic Valve Replacement), edoxaban-treated patients showed significantly higher Treatment Satisfaction and Convenience scores compared with VKA-treated patients across all time points. Among edoxaban-treated patients, those who received VKAs pre-TAVR were reportedly more satisfied with treatment than those who received non-vitamin K oral anticoagulants (NOACs) or NOACs/VKAs.

Based on the above results, it can be concluded that patients with atrial fibrillation who were administered edoxaban post-TAVR may show significantly higher Treatment Satisfaction and Convenience scores compared with those who received VKAs.

button
2Min Read
15 Jul

Long-term effects of bariatric surgery on hypertension in patients with obesity

A recent study found that bariatric surgery presented an effective and durable strategy for high blood pressure in obese patients. The conclusions of this study were published in The Journal of the American College of Cardiology.

In this randomized clinical trial, 100 participants with grade 1 or 2 obesity with hypertension and using a minimum of two medications were enrolled. These individuals were randomly allocated to receive either Roux-en-Y gastric bypass (RYGB) in conjunction with medical therapy (MT) or MT alone.  The original primary outcome of the study was lessening at least 30% of the total antihypertensive medications, while still maintaining blood pressure levels at <140/90 mm Hg at 5 years.

At the end of 5 years, it was observed that BMI (body mass index) was 36.40 kg/m2 and 28.01 kg/m2 for MT and RYGB. RYGB showed a greater rate in the number of medication reduction when compared to MT. The mean number of antihypertensive medications was 2.97 and 0.80 for MT and RYGB, respectively. Hypertensive remission rates were 2.4% vs 46.9%.

Based on the above results, it can be concluded that the rate of resistant hypertension may be lower after RYGB, thus showing that bariatric surgery may offer an effective and durable strategy to control high blood pressure in patients suffering from obesity.

Long-term effects of bariatric surgery on hypertension in patients with obesity

A recent study found that bariatric surgery presented an effective and durable strategy for high blood pressure in obese patients. The conclusions of this study were published in The Journal of the American College of Cardiology.

In this randomized clinical trial, 100 participants with grade 1 or 2 obesity with hypertension and using a minimum of two medications were enrolled. These individuals were randomly allocated to receive either Roux-en-Y gastric bypass (RYGB) in conjunction with medical therapy (MT) or MT alone.  The original primary outcome of the study was lessening at least 30% of the total antihypertensive medications, while still maintaining blood pressure levels at <140/90 mm Hg at 5 years.

At the end of 5 years, it was observed that BMI (body mass index) was 36.40 kg/m2 and 28.01 kg/m2 for MT and RYGB. RYGB showed a greater rate in the number of medication reduction when compared to MT. The mean number of antihypertensive medications was 2.97 and 0.80 for MT and RYGB, respectively. Hypertensive remission rates were 2.4% vs 46.9%.

Based on the above results, it can be concluded that the rate of resistant hypertension may be lower after RYGB, thus showing that bariatric surgery may offer an effective and durable strategy to control high blood pressure in patients suffering from obesity.

button
2Min Read
15 Jul

Long-term effects of bariatric surgery on hypertension in patients with obesity

A recent study found that bariatric surgery presented an effective and durable strategy for high blood pressure in obese patients. The conclusions of this study were published in The Journal of the American College of Cardiology.

In this randomized clinical trial, 100 participants with grade 1 or 2 obesity with hypertension and using a minimum of two medications were enrolled. These individuals were randomly allocated to receive either Roux-en-Y gastric bypass (RYGB) in conjunction with medical therapy (MT) or MT alone.  The original primary outcome of the study was lessening at least 30% of the total antihypertensive medications, while still maintaining blood pressure levels at <140/90 mm Hg at 5 years.

At the end of 5 years, it was observed that BMI (body mass index) was 36.40 kg/m2 and 28.01 kg/m2 for MT and RYGB. RYGB showed a greater rate in the number of medication reduction when compared to MT. The mean number of antihypertensive medications was 2.97 and 0.80 for MT and RYGB, respectively. Hypertensive remission rates were 2.4% vs 46.9%.

Based on the above results, it can be concluded that the rate of resistant hypertension may be lower after RYGB, thus showing that bariatric surgery may offer an effective and durable strategy to control high blood pressure in patients suffering from obesity.

button
2Min Read
09 Jul

Use of lung ultrasound B-lines to assist physicians to tailor diuretic therapy in lung congestion of heart failure patients

According to a recent study, lung ultrasound (LUS) B-lines may be useful for assistant physicians to tailor diuretic therapy to each patient's congestion status in case of heart failure (HF). This study was published in the journal, Clinical Research in Cardiology.

This prospective, randomized, single-blinded trial included 139 patients who were either randomized to the blind LUS (n=70) or open 8-zone LUS (n=69). The primary outcome of the study was change in loop diuretic dose that included up- or down-titration.

At the end of the study, it was found that up- and down-titration of furosemide dose changes were most frequently seen among those patients in whom the LUS results were open to the assistant physician, which was 13 in blind LUS versus 22 in open LUS. These dose changes were more frequent and significantly correlated in case of open LUS where the number of B-lines was available to the assistant physician. As a result, the clinicians were more likely to up-titrate furosemide dose in case of “presence of pulmonary congestion” and more likely to decrease furosemide dose in case of "absence of pulmonary congestion".

Based on the above results, it can be concluded that results of LUS B-lines to assistant physicians may allow both up- and down-titration as part of loop diuretic changes which may be utilized to tailor diuretic therapy for each patient with congestion status.

Use of lung ultrasound B-lines to assist physicians to tailor diuretic therapy in lung congestion of heart failure patients

According to a recent study, lung ultrasound (LUS) B-lines may be useful for assistant physicians to tailor diuretic therapy to each patient's congestion status in case of heart failure (HF). This study was published in the journal, Clinical Research in Cardiology.

This prospective, randomized, single-blinded trial included 139 patients who were either randomized to the blind LUS (n=70) or open 8-zone LUS (n=69). The primary outcome of the study was change in loop diuretic dose that included up- or down-titration.

At the end of the study, it was found that up- and down-titration of furosemide dose changes were most frequently seen among those patients in whom the LUS results were open to the assistant physician, which was 13 in blind LUS versus 22 in open LUS. These dose changes were more frequent and significantly correlated in case of open LUS where the number of B-lines was available to the assistant physician. As a result, the clinicians were more likely to up-titrate furosemide dose in case of “presence of pulmonary congestion” and more likely to decrease furosemide dose in case of "absence of pulmonary congestion".

Based on the above results, it can be concluded that results of LUS B-lines to assistant physicians may allow both up- and down-titration as part of loop diuretic changes which may be utilized to tailor diuretic therapy for each patient with congestion status.

button
2Min Read
09 Jul

Use of lung ultrasound B-lines to assist physicians to tailor diuretic therapy in lung congestion of heart failure patients

According to a recent study, lung ultrasound (LUS) B-lines may be useful for assistant physicians to tailor diuretic therapy to each patient's congestion status in case of heart failure (HF). This study was published in the journal, Clinical Research in Cardiology.

This prospective, randomized, single-blinded trial included 139 patients who were either randomized to the blind LUS (n=70) or open 8-zone LUS (n=69). The primary outcome of the study was change in loop diuretic dose that included up- or down-titration.

At the end of the study, it was found that up- and down-titration of furosemide dose changes were most frequently seen among those patients in whom the LUS results were open to the assistant physician, which was 13 in blind LUS versus 22 in open LUS. These dose changes were more frequent and significantly correlated in case of open LUS where the number of B-lines was available to the assistant physician. As a result, the clinicians were more likely to up-titrate furosemide dose in case of “presence of pulmonary congestion” and more likely to decrease furosemide dose in case of "absence of pulmonary congestion".

Based on the above results, it can be concluded that results of LUS B-lines to assistant physicians may allow both up- and down-titration as part of loop diuretic changes which may be utilized to tailor diuretic therapy for each patient with congestion status.

button